Understanding the FDA’s Draft Guidance on Computer Software Assurance for Medical Devices & Bio/Pharma
The FDA’s draft guidance on computer software assurance for medical devices and bio/pharma sectors marks a significant shift in regulatory expectations. This guidance – aimed at optimizing software validation practices – addresses the evolving needs of an industry increasingly reliant on digital solutions. Here is an exploration of the nuances